作者: Y. S. Bakhle
DOI: 10.1007/978-3-642-65600-2_3
关键词: Internal medicine 、 In vitro 、 Chemistry 、 Enzyme 、 Substrate (chemistry) 、 In vivo 、 Endocrinology 、 Salt solution 、 Angiotensin-converting enzyme 、 Renin–angiotensin system 、 Perfusion
摘要: In 1954 Skeggs, Marsh, Kahn and Shumway reported that angiotensin, the pressor product of renin’s incubation with its substrate, was actually a mixture two forms, Ang. I II, separable by counter-current distribution. I, initial action, itself transformed into II an enzyme present in plasma requiring chloride ion for activity. This enzymic activity called “converting enzyme”. Since were equally (when injected intravenously rats), they suggested action converting removal some groups from “leaving portion molecule responsible unchanged”. The following year Helmer (1955) showed there pharmacological difference between being inactive active contracting rabbit aortic strip. He also would convert to vitro, although both forms equipressor vivo. Following this suggestion true vasoconstrictor agent, Skeggs et al. (1956) isolated kidneys perfused artificial salt solution, only increased perfusion pressure not I. From these experiments, concluded enough (CE) transform so that, vivo, equipressor, rate-limiting step overall formation rate reaction renin substrate.